A new RSV shot for babies is in such short supply that doctors have been advised to prioritize giving the drug to infants at high risk of severe disease

Date:

Share:

[ad_1]

A new shot for infants against RSV is in short supply, and U.S. health officials told doctors they should prioritize giving the drug to babies at the highest risk of severe disease.

Infants less than 6 months who have chronic lung disease or other underlying conditions should be given priority, the Centers for Disease Control and Prevention told doctors in a Monday evening advisory.

RSV, or respiratory syncytial virus, is a common cause of cold-like symptoms that can be dangerous for young children. A seasonal virus, it’s being widely reported in the southern United States and is expected to continue to spread over the next month or two.

The new, one-time shot is a lab-made antibody that helps the immune system fight off the virus. Sold under the brand name Beyfortus, the drug was developed by AstraZeneca and Sanofi.

In July, the U.S. Food and Drug Administration approved it, and the next month the CDC recommended it for infants born just before or during the RSV season and for those less than 8 months old before the season starts. They also recommended a dose for some 8- to 19-months-olds at higher risk of a serious illness.

It comes in prefilled syringes in doses of 50 milligrams or 100 milligrams. The larger doses are for larger, heavier infants.

In a recent letter to state immunization managers, the CDC said there would be a pause on orders for the shots made through a program that pays for vaccines for poor and uninsured children. On Monday, the CDC put out a more general alert to U.S. doctors.

In a statement, Sanofi said demand — especially for the larger doses — “has been higher than anticipated.”

Indeed, there’s not enough to protect all the kids who are eligible for the larger shots, health officials say. Supply of the smaller doses also may be limited during the current RSV season, CDC officials said. The CDC said doctors should not use two smaller doses on larger infants, so as to preserve the supply of those shots.

Some children may be eligible for an older RSV drug, palivizumab, agency officials said. That drug requires monthly injections.

Doctors also are being urged to try to persuade pregnant women to get a new vaccine designed to protect newborns from RSV. When that happens, the baby doesn’t need the antibody drug.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

[ad_2]

Source link

Subscribe to our magazine

━ more like this

Crypto Crime Investigation (C.C.I) Enhances Singapore’s Safety with Innovative Pig Butchering Fraud Recovery Technology

Crypto Crime Investigation (C.C.I) is proud to announce the launch of its groundbreaking Pig Butchering fraud recovery technology, a vital initiative aimed at protecting...

U.S. Treasury removes Francisco Javier D’Agostino from sanctions list after independent review

The United States Treasury Department has removed Francisco Javier D'Agostino from its sanctions list following an independent review that confirmed his business activities were...

Expert Forensic Analysis in Investigating Crypto Investment Scams and Recovering Lost Funds

The allure of cryptocurrency investment, with its potential for high returns, has unfortunately attracted a darker side: sophisticated and deceptive scams. Victims of these...

Asia’s Certified Cryptocurrency Investigator Launches in Singapore: Pioneering Crypto Crime Investigation (C.C.I)

Singapore, – In a groundbreaking move to enhance digital asset security and bolster consumer confidence in the cryptocurrency market, the Crypto Crime  Investigation...

C.C.I Launches as the Ultimate Recovery Platform for Crypto Investors Targeted by Scams

Nevada, Florida – In response to the growing concern over cryptocurrency investment scams, C.C.I (Crypto Crime Investigation) proudly announces its official launch as the...